Daniel Lawrence Faden, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Oropharyngeal Neoplasms | 14 | 2023 | 477 | 4.490 |
Why?
|
Papillomavirus Infections | 18 | 2023 | 1587 | 4.280 |
Why?
|
Head and Neck Neoplasms | 21 | 2024 | 2734 | 3.770 |
Why?
|
Paranasal Sinus Neoplasms | 4 | 2023 | 234 | 2.240 |
Why?
|
Carcinoma, Squamous Cell | 13 | 2023 | 4034 | 1.880 |
Why?
|
Papillomaviridae | 10 | 2023 | 1119 | 1.400 |
Why?
|
Human papillomavirus 16 | 6 | 2023 | 262 | 1.170 |
Why?
|
Alphapapillomavirus | 4 | 2022 | 221 | 1.160 |
Why?
|
Genome, Viral | 3 | 2021 | 667 | 0.770 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2023 | 286 | 0.720 |
Why?
|
Nasal Obstruction | 1 | 2021 | 151 | 0.670 |
Why?
|
HLA-C Antigens | 1 | 2019 | 147 | 0.660 |
Why?
|
Receptors, KIR | 1 | 2019 | 113 | 0.660 |
Why?
|
Nerve Sheath Neoplasms | 1 | 2020 | 190 | 0.650 |
Why?
|
Skull Base | 2 | 2019 | 306 | 0.640 |
Why?
|
Tongue Neoplasms | 2 | 2016 | 180 | 0.610 |
Why?
|
DNA, Viral | 6 | 2023 | 2225 | 0.580 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2017 | 79 | 0.570 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 604 | 0.570 |
Why?
|
Levamisole | 1 | 2016 | 35 | 0.560 |
Why?
|
Neurofibroma | 1 | 2017 | 106 | 0.560 |
Why?
|
Nasal Polyps | 1 | 2021 | 360 | 0.540 |
Why?
|
Neck | 1 | 2020 | 697 | 0.540 |
Why?
|
Airway Obstruction | 1 | 2021 | 664 | 0.540 |
Why?
|
Neurofibromin 1 | 1 | 2017 | 196 | 0.520 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 2016 | 90 | 0.520 |
Why?
|
Aneurysm, False | 1 | 2018 | 276 | 0.510 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 1061 | 0.510 |
Why?
|
DNA, Neoplasm | 4 | 2024 | 1758 | 0.500 |
Why?
|
Carotid Arteries | 1 | 2018 | 952 | 0.450 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 2014 | 139 | 0.450 |
Why?
|
Neck Dissection | 1 | 2014 | 197 | 0.450 |
Why?
|
Sensory Thresholds | 1 | 2014 | 391 | 0.450 |
Why?
|
Mutagenesis | 3 | 2021 | 1266 | 0.420 |
Why?
|
Vasculitis | 1 | 2016 | 519 | 0.410 |
Why?
|
Neurofibromatosis 1 | 1 | 2017 | 569 | 0.400 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2023 | 2020 | 0.390 |
Why?
|
Mutation | 8 | 2023 | 29786 | 0.390 |
Why?
|
Endoscopy | 2 | 2018 | 1785 | 0.380 |
Why?
|
Neurosurgical Procedures | 2 | 2019 | 2002 | 0.360 |
Why?
|
Electromyography | 1 | 2014 | 1379 | 0.340 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2016 | 2948 | 0.330 |
Why?
|
Electric Stimulation Therapy | 1 | 2014 | 605 | 0.330 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.320 |
Why?
|
Immunotherapy | 2 | 2024 | 4445 | 0.310 |
Why?
|
Monitoring, Intraoperative | 1 | 2014 | 957 | 0.310 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9239 | 0.300 |
Why?
|
Ultrasonography | 1 | 2020 | 5985 | 0.290 |
Why?
|
Laryngeal Neoplasms | 2 | 2020 | 512 | 0.280 |
Why?
|
Humans | 46 | 2024 | 744343 | 0.280 |
Why?
|
Prolapse | 1 | 2021 | 68 | 0.200 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 362 | 0.200 |
Why?
|
Middle Aged | 19 | 2023 | 213383 | 0.190 |
Why?
|
Interferon-gamma | 2 | 2019 | 3206 | 0.190 |
Why?
|
Pharyngeal Neoplasms | 1 | 2020 | 117 | 0.190 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2023 | 3597 | 0.180 |
Why?
|
Receptors, KIR3DL2 | 1 | 2019 | 1 | 0.170 |
Why?
|
Multilevel Analysis | 1 | 2019 | 142 | 0.170 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 973 | 0.170 |
Why?
|
Glottis | 1 | 2020 | 217 | 0.160 |
Why?
|
Free Tissue Flaps | 1 | 2023 | 328 | 0.160 |
Why?
|
Postoperative Period | 1 | 2024 | 1842 | 0.160 |
Why?
|
Adult | 15 | 2023 | 214055 | 0.160 |
Why?
|
HLA-A Antigens | 1 | 2019 | 231 | 0.160 |
Why?
|
Laryngectomy | 1 | 2020 | 248 | 0.160 |
Why?
|
Alkaloids | 1 | 2019 | 190 | 0.160 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2019 | 118 | 0.150 |
Why?
|
Retrospective Studies | 12 | 2024 | 77449 | 0.150 |
Why?
|
Propensity Score | 1 | 2024 | 1781 | 0.150 |
Why?
|
Female | 17 | 2023 | 380194 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4803 | 0.130 |
Why?
|
Mouth Neoplasms | 1 | 2020 | 601 | 0.130 |
Why?
|
DNA | 3 | 2023 | 7301 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1265 | 0.120 |
Why?
|
SEER Program | 1 | 2019 | 1508 | 0.120 |
Why?
|
Neoplasms | 1 | 2023 | 21683 | 0.120 |
Why?
|
Carcinogens | 1 | 2016 | 466 | 0.120 |
Why?
|
Polymerase Chain Reaction | 1 | 2023 | 6171 | 0.120 |
Why?
|
Aged | 10 | 2023 | 163280 | 0.120 |
Why?
|
Kinetics | 1 | 2022 | 6473 | 0.120 |
Why?
|
Pain, Postoperative | 2 | 2021 | 1643 | 0.120 |
Why?
|
Male | 16 | 2023 | 350118 | 0.120 |
Why?
|
Germ Cells | 1 | 2017 | 631 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2020 | 12959 | 0.110 |
Why?
|
Epitopes | 1 | 2019 | 2571 | 0.110 |
Why?
|
Aged, 80 and over | 6 | 2022 | 57776 | 0.110 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1366 | 0.110 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4933 | 0.110 |
Why?
|
Angiography | 1 | 2018 | 1639 | 0.100 |
Why?
|
Evolution, Molecular | 1 | 2021 | 1940 | 0.100 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1788 | 0.100 |
Why?
|
Vocal Cords | 1 | 2016 | 528 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1329 | 0.100 |
Why?
|
Teaching | 1 | 2019 | 1174 | 0.100 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11031 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2023 | 3022 | 0.090 |
Why?
|
Killer Cells, Natural | 1 | 2019 | 2133 | 0.090 |
Why?
|
Up-Regulation | 1 | 2019 | 4217 | 0.090 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 4328 | 0.080 |
Why?
|
Biopsy | 1 | 2020 | 6756 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39050 | 0.080 |
Why?
|
Analgesics, Opioid | 2 | 2021 | 3674 | 0.080 |
Why?
|
Databases, Factual | 2 | 2021 | 7729 | 0.080 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3586 | 0.070 |
Why?
|
Contrast Media | 1 | 2020 | 5300 | 0.070 |
Why?
|
ROC Curve | 1 | 2014 | 3527 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2065 | 0.070 |
Why?
|
Antirheumatic Agents | 1 | 2016 | 1339 | 0.070 |
Why?
|
Prevalence | 2 | 2020 | 15226 | 0.070 |
Why?
|
Tomography, X-Ray Computed | 2 | 2020 | 20129 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11366 | 0.070 |
Why?
|
Base Sequence | 1 | 2017 | 12797 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9438 | 0.060 |
Why?
|
Radiotherapy Dosage | 2 | 2021 | 2879 | 0.060 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16689 | 0.050 |
Why?
|
Young Adult | 3 | 2020 | 56430 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 35421 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2021 | 63114 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15519 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2017 | 8428 | 0.050 |
Why?
|
Incidence | 2 | 2016 | 20947 | 0.050 |
Why?
|
Forearm | 1 | 2023 | 409 | 0.050 |
Why?
|
Radius | 1 | 2023 | 422 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 481 | 0.040 |
Why?
|
Cohort Studies | 2 | 2019 | 40561 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 705 | 0.040 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29063 | 0.030 |
Why?
|
Signal Transduction | 1 | 2019 | 23403 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2020 | 1770 | 0.030 |
Why?
|
Nose | 1 | 2019 | 509 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
Blood Loss, Surgical | 1 | 2019 | 662 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2022 | 2924 | 0.030 |
Why?
|
Time Factors | 1 | 2016 | 40075 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3271 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4751 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2021 | 13033 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17446 | 0.030 |
Why?
|
Risk Factors | 1 | 2019 | 72290 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2020 | 3479 | 0.030 |
Why?
|
Adolescent | 2 | 2023 | 85781 | 0.030 |
Why?
|
United States | 1 | 2019 | 69872 | 0.030 |
Why?
|
Metagenome | 1 | 2014 | 418 | 0.020 |
Why?
|
Smoking | 2 | 2020 | 8987 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3218 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2297 | 0.020 |
Why?
|
Pain | 1 | 2023 | 4986 | 0.020 |
Why?
|
Age Distribution | 1 | 2014 | 2902 | 0.020 |
Why?
|
Length of Stay | 1 | 2021 | 6309 | 0.020 |
Why?
|
Genetic Variation | 1 | 2022 | 6544 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 12951 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3616 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2022 | 21746 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18370 | 0.010 |
Why?
|
Clinical Competence | 1 | 2019 | 4687 | 0.010 |
Why?
|
Genomics | 1 | 2014 | 5720 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2019 | 15295 | 0.010 |
Why?
|
Mice | 1 | 2021 | 81183 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 23338 | 0.010 |
Why?
|
Animals | 1 | 2021 | 168757 | 0.010 |
Why?
|